CY1111252T1 - Ιατρικες συνθεσεις για ενδοκυστικη αγωγη του καρκινου της ουροδοχου κυστεως - Google Patents

Ιατρικες συνθεσεις για ενδοκυστικη αγωγη του καρκινου της ουροδοχου κυστεως

Info

Publication number
CY1111252T1
CY1111252T1 CY20111100183T CY111100183T CY1111252T1 CY 1111252 T1 CY1111252 T1 CY 1111252T1 CY 20111100183 T CY20111100183 T CY 20111100183T CY 111100183 T CY111100183 T CY 111100183T CY 1111252 T1 CY1111252 T1 CY 1111252T1
Authority
CY
Cyprus
Prior art keywords
cancer
formulation
cysteous
introduction
medical compositions
Prior art date
Application number
CY20111100183T
Other languages
Greek (el)
English (en)
Inventor
Bastiaan Nuijen
Ernie Pfadenhauer
Jos F Beijen
Original Assignee
Spectrum Pharmaceauticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Spectrum Pharmaceauticals, Inc. filed Critical Spectrum Pharmaceauticals, Inc.
Publication of CY1111252T1 publication Critical patent/CY1111252T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CY20111100183T 2001-11-01 2011-02-14 Ιατρικες συνθεσεις για ενδοκυστικη αγωγη του καρκινου της ουροδοχου κυστεως CY1111252T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34444601P 2001-11-01 2001-11-01
EP06077149A EP1864660B1 (en) 2001-11-01 2002-11-01 Medical compositions for intravesical treatment of bladder cancer

Publications (1)

Publication Number Publication Date
CY1111252T1 true CY1111252T1 (el) 2015-08-05

Family

ID=23350584

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20111100183T CY1111252T1 (el) 2001-11-01 2011-02-14 Ιατρικες συνθεσεις για ενδοκυστικη αγωγη του καρκινου της ουροδοχου κυστεως

Country Status (12)

Country Link
US (6) US6894071B2 (https=)
EP (3) EP2060259B1 (https=)
JP (1) JP4317452B2 (https=)
AT (2) ATE493126T1 (https=)
AU (1) AU2002350115A1 (https=)
CA (2) CA2789114C (https=)
CY (1) CY1111252T1 (https=)
DE (2) DE60235214D1 (https=)
DK (2) DK2060259T3 (https=)
ES (2) ES2341922T3 (https=)
PT (2) PT1864660E (https=)
WO (1) WO2003037314A2 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE493126T1 (de) * 2001-11-01 2011-01-15 Spectrum Pharmaceuticals Inc Medizinische zusammensetzungen zur intravesikalen behandlung von blasenkrebs
US20080227841A1 (en) * 2007-03-13 2008-09-18 Luigi Lenaz Intravesical apaziquone administration following transurethral resection
US8563592B2 (en) * 2001-11-01 2013-10-22 Spectrum Pharmaceuticals, Inc. Bladder cancer treatment and methods
US8361490B2 (en) 2004-09-16 2013-01-29 Theracoat Ltd. Biocompatible drug delivery apparatus and methods
AU2006230582A1 (en) * 2005-03-31 2006-10-05 Spectrum Pharmaceuticals, Inc. Indoloquinone tumor radiation sensitization
CA2653541C (en) 2005-06-06 2014-12-23 The University Of British Columbia Polymer-based serum albumin substitute
JP2009526085A (ja) * 2006-02-09 2009-07-16 スペクトラム ファーマシューティカルズ インコーポレイテッド Ｅｏ９およびプロピレングリコールの使用による膀胱癌の治療
US20080114021A1 (en) * 2006-11-09 2008-05-15 University Of Maryland Baltimore Use Of 5,6-Dimethylxanthenone-4-Acetic Acid as an Antimicrobial Agent
RU2354386C1 (ru) * 2007-12-26 2009-05-10 ГУ Московская городская онкологическая больница №62 Департамента здравоохранения г. Москвы Способ профилактики рецидивов поверхностного рака мочевого пузыря
GB0800311D0 (en) * 2008-01-09 2008-02-20 Cytosystems Ltd Apparatus and method for filtering biological material
ES2732150T3 (es) 2010-01-20 2019-11-20 Urogen Pharma Ltd Material y método para tratar cavidades internas
CN102906157B (zh) 2010-03-01 2016-08-24 不列颠哥伦比亚大学 衍生的超支化聚丙三醇
PT2619331T (pt) * 2010-09-22 2018-06-01 Univ Texas Métodos de tratamento de cancro incluindo rastreio de nqo1
EP2734187B1 (en) 2011-07-20 2018-09-05 UroGen Pharma Ltd. Materials and method for treating internal body cavities
HUE032240T2 (en) 2011-10-24 2017-09-28 Asana Biosciences Llc cyclohexylamines
WO2014062856A1 (en) 2012-10-16 2014-04-24 Halozyme, Inc. Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods
JP6616772B2 (ja) 2013-12-16 2019-12-04 アサナ・バイオサイエンシズ，リミテッド・ライアビリティ・カンパニー Ｐ２ｘ３および／またはｐ２ｘ２／３化合物ならびに方法
CN104743887B (zh) * 2014-09-22 2016-03-23 巨石集团有限公司 一种玻璃纤维组合物及其玻璃纤维和复合材料
CN109996546B (zh) 2016-09-30 2023-06-27 阿沙纳生物科学公司 P2x3和/或p2x2/3化合物及方法
WO2020168244A1 (en) 2019-02-15 2020-08-20 Incelldx, Inc. Assaying bladder-associated samples, identifying and treating bladder-associated neoplasia, and kits for use therein
CN112220742A (zh) * 2019-07-15 2021-01-15 深圳艾欣达伟医药科技有限公司 稳定的ast-3424注射液制剂及制备方法

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3993754A (en) * 1974-10-09 1976-11-23 The United States Of America As Represented By The United States Energy Research And Development Administration Liposome-encapsulated actinomycin for cancer chemotherapy
JPS54151134A (en) 1978-05-19 1979-11-28 Kureha Chem Ind Co Ltd Antitumorigenic agent
NL8001280A (nl) * 1980-03-04 1981-10-01 Philips Nv Lagedrukontladingslamp.
AU565354B2 (en) 1983-11-14 1987-09-10 Bio-Mimetics Inc. Bioadhesive compositions and methods of treatment therewith
US4898729A (en) 1983-12-09 1990-02-06 Euroceltique, S.A. Treatment of hypertension, compounds and compositions for antihypertension and diuresis
US4671954A (en) * 1983-12-13 1987-06-09 University Of Florida Microspheres for incorporation of therapeutic substances and methods of preparation thereof
JPS60163621A (ja) 1984-02-02 1985-08-26 村上　俊文 紙製便座カバ−の製造方法
JPS60163821A (ja) 1984-02-03 1985-08-26 Tdk Corp フエライト粒子を含む薬剤用担体
JPS61189215A (ja) 1985-02-18 1986-08-22 Teijin Ltd ５−フルオロ−２′−デオキシウリジンエステル類の油状医薬組成物
WO1987006227A2 (en) * 1986-04-17 1987-10-22 Jouhar Akbar Jan Indoloquinone compounds
US4871542A (en) * 1987-04-30 1989-10-03 Ferring Service Center, N.V. Method and apparatus useful for delivering medicinal compositions into the bladder and urinary tract
EP0331635A3 (en) 1988-02-29 1990-02-28 The Board of Regents of the University of Texas System Preparations for treating bladder cancer
EP0338679A3 (en) 1988-03-24 1991-03-06 Genentech, Inc. Tumour necrosis factor in the treatment of bladder cancer
FR2629584B1 (fr) 1988-03-31 1993-06-04 France Etat Armement Dispositif de stabilisation pour un projectile a faible moment d'inertie longitudinal tire a partir d'un tube raye
US5843156A (en) * 1988-08-24 1998-12-01 Endoluminal Therapeutics, Inc. Local polymeric gel cellular therapy
US5744166A (en) * 1989-02-25 1998-04-28 Danbiosyst Uk Limited Drug delivery compositions
PT93772A (pt) * 1989-04-17 1991-01-08 Searle & Co Processo para a preparacao de composicoes para o tratamento de neoplasias, contendo um agente anti-neoplastico, por exemplo doxorubicina e um agente protector para reduzir os efeitos secundarios, por exemplo carbetimer
US5216011A (en) * 1989-09-01 1993-06-01 Bristol-Myers Squibb Co. Stable solutions of mitomycin c
US5237466A (en) 1989-11-02 1993-08-17 International Business Machines Corporation Method and apparatus for programmably controlling spindle synchronization and phase among disk drives in a storage subsystem
FI84874C (fi) 1989-11-02 1992-02-10 Valio Meijerien Foerfarande foer inkapsling av biologiskt aktiva aemnen, enligt metoden framstaelld kapsel, dess anvaendning och foder innehaollande den.
US5292516A (en) * 1990-05-01 1994-03-08 Mediventures, Inc. Body cavity drug delivery with thermoreversible gels containing polyoxyalkylene copolymers
US5346703A (en) * 1990-08-07 1994-09-13 Mediventures, Inc. Body cavity drug delivery with thermo-irreversible polyoxyalkylene and ionic polysaccharide gels
IT1250421B (it) 1991-05-30 1995-04-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato con proprieta' bio-adesive.
US5550110A (en) 1992-04-22 1996-08-27 Warner-Lambert Company Endothelin Antagonists II
JP3598049B2 (ja) 1992-09-18 2004-12-08 山之内製薬株式会社 ハイドロゲル徐放性製剤
US5744155A (en) * 1993-08-13 1998-04-28 Friedman; Doron Bioadhesive emulsion preparations for enhanced drug delivery
EP0995447A1 (en) 1993-09-09 2000-04-26 Takeda Chemical Industries, Ltd. Formulation comprising antibacterial substance and antiulcer substance
CA2135151A1 (en) 1993-11-08 1995-05-09 Mitsuhiro Wakimasu Cyclic hexapeptides, their production and use
US5405622A (en) * 1993-12-22 1995-04-11 Vernice; Joseph Gamma radiation resistant lubricating gel
TW438601B (en) * 1994-05-18 2001-06-07 Janssen Pharmaceutica Nv New mucoadhesive emulsion compositions and a process for the preparation thereof
US5811416A (en) 1994-06-06 1998-09-22 Board Of Regents The University Of Texas System Endothelin antagonist and/or endothelin synthase inhibitor in combination with a progestin, an estrogen, a cyclooxygenase inhibitor, or a nitric acid donor or substrate
US5612359A (en) 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
EP2301562B1 (en) 1994-12-12 2013-04-17 Omeros Corporation Irrigation solution and method for inhibition of pain, inflammation and spasm
US5749845A (en) * 1995-01-25 1998-05-12 Iotek, Inc. Delivering an agent to an organ
WO1997023456A1 (en) 1995-12-21 1997-07-03 British Technology Group Ltd. Indoloquinone derivatives as bioreductive agents
US5985312A (en) * 1996-01-26 1999-11-16 Brown University Research Foundation Methods and compositions for enhancing the bioadhesive properties of polymers
JP2000509014A (ja) * 1996-03-11 2000-07-18 フォーカル，インコーポレイテッド 放射性核種および放射性医薬品のポリマー送達
US5955096A (en) * 1996-06-25 1999-09-21 Brown University Research Foundation Methods and compositions for enhancing the bioadhesive properties of polymers using organic excipients
US6251861B1 (en) 1996-06-27 2001-06-26 Takeda Chemical Industries, Ltd. Treatment of cerebral infarction using cyclic hexapeptides
JP2967734B2 (ja) * 1996-10-18 1999-10-25 日本電気株式会社 薄膜の形成方法
EP0971641A4 (en) * 1997-04-03 2003-08-13 Point Biomedical Corp SYSTEM FOR THE ADMINISTRATION OF AN INTRAVESICAL MEDICINAL PRODUCT
US5854382A (en) * 1997-08-18 1998-12-29 Meadox Medicals, Inc. Bioresorbable compositions for implantable prostheses
AU9082698A (en) * 1997-09-08 1999-03-29 Theramark Limited Treatment of inflammatory conditions
US6156744A (en) 1998-03-19 2000-12-05 Cancer Research Campaign Tech (London) DT-diaphorase directed anti-tumor agents
EP0950418A2 (en) 1998-04-14 1999-10-20 Takeda Chemical Industries, Ltd. Composition for preventing or treating ischemic disease
US6171610B1 (en) * 1998-04-24 2001-01-09 University Of Massachusetts Guided development and support of hydrogel-cell compositions
KR20010043322A (ko) 1998-05-05 2001-05-25 아스트라제네카 악티에볼라그 미코박테리아성 억제제
IL124957A0 (en) 1998-06-16 1999-01-26 Univ Ben Gurion Active ingredient delivery systems and devices based on porous matrices
US6087396A (en) * 1998-10-05 2000-07-11 Situs Corporation Oxybutynin formulations and method of use
GB9827034D0 (en) 1998-12-10 1999-02-03 Univ Manchester Delivery formulation
JP2000256182A (ja) 1999-03-03 2000-09-19 Kazuhiro Morimoto 抗菌製剤
WO2000067023A1 (en) 1999-04-29 2000-11-09 Coley Pharmaceutical Gmbh Screening for immunostimulatory dna functional modifyers
US7566452B1 (en) 1999-05-04 2009-07-28 New York University Cancer treatment with endothelin receptor antagonists
US6545048B1 (en) 1999-06-29 2003-04-08 California Institute Of Technology Compositions and methods of treating cancer using compositions comprising an inhibitor or endothelin receptor activity
WO2001091736A2 (en) 2000-05-31 2001-12-06 Warner-Lambert Company Combinations of an endothelin receptor antagonist and an antiepileptic compound having pain alleviating properties or analgesic
MXPA03004832A (es) 2000-12-01 2004-05-04 Guilford Pharm Inc Compuestos y sus usos.
WO2002049630A2 (en) 2000-12-21 2002-06-27 Bristol-Myers Squibb Company Method for preventing or treating pain by administering an endothelin antagonist
WO2003009805A2 (en) 2001-07-23 2003-02-06 Brigham And Women's Hospital, Inc. Analgesic methods using endothelin receptor ligands
ATE493126T1 (de) 2001-11-01 2011-01-15 Spectrum Pharmaceuticals Inc Medizinische zusammensetzungen zur intravesikalen behandlung von blasenkrebs
US7973064B2 (en) 2001-11-27 2011-07-05 The Board Of Trustees Of The University Of Illinois Method and composition for potentiating an opiate analgesic
JP5184738B2 (ja) 2002-05-03 2013-04-17 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 修飾第ｖｉｉ因子の安定化された固体組成物
US20040009918A1 (en) 2002-05-03 2004-01-15 Hanne Nedergaard Stabilised solid compositions of modified factor VII
JP2006508086A (ja) 2002-10-24 2006-03-09 ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ イリノイ 固形腫瘍を予防および治療するための方法および組成物
HRP20140338T1 (hr) 2005-07-25 2014-06-20 Emergent Product Development Seattle, Llc Smanjenje broja b-stanica upotrebom molekula koje se specifiäśno vežu na cd37 i cd20
JP2009526085A (ja) 2006-02-09 2009-07-16 スペクトラム ファーマシューティカルズ インコーポレイテッド Ｅｏ９およびプロピレングリコールの使用による膀胱癌の治療

Also Published As

Publication number Publication date
US7977369B2 (en) 2011-07-12
EP1864660B1 (en) 2010-12-29
EP1439835A2 (en) 2004-07-28
JP4317452B2 (ja) 2009-08-19
US6894071B2 (en) 2005-05-17
EP1864660A2 (en) 2007-12-12
US20120252861A1 (en) 2012-10-04
EP2060259A1 (en) 2009-05-20
US20080166402A1 (en) 2008-07-10
US8648108B2 (en) 2014-02-11
PT2060259E (pt) 2010-04-26
ATE455545T1 (de) 2010-02-15
US20030133954A1 (en) 2003-07-17
ES2384208T3 (es) 2012-07-02
JP2005532986A (ja) 2005-11-04
DK2060259T3 (da) 2010-05-17
PT1864660E (pt) 2011-03-31
DK1864660T3 (da) 2011-02-21
DE60235214D1 (de) 2010-03-11
HK1132181A1 (en) 2010-02-19
WO2003037314A2 (en) 2003-05-08
ATE493126T1 (de) 2011-01-15
US20050215615A1 (en) 2005-09-29
US20070010570A1 (en) 2007-01-11
CA2466148C (en) 2013-01-08
EP2060259B1 (en) 2010-01-20
DE60238798D1 (de) 2011-02-10
CA2466148A1 (en) 2003-05-08
US20090076123A1 (en) 2009-03-19
CA2789114A1 (en) 2003-05-08
EP1864660A3 (en) 2008-04-23
WO2003037314A3 (en) 2003-10-16
AU2002350115A1 (en) 2003-05-12
CA2789114C (en) 2014-03-25
ES2341922T3 (es) 2010-06-29

Similar Documents

Publication Publication Date Title
CY1111252T1 (el) Ιατρικες συνθεσεις για ενδοκυστικη αγωγη του καρκινου της ουροδοχου κυστεως
NO2022001I1 (no) Pazopanib
NZ542138A (en) Heterobifunctional polymeric bioconjugates
WO2003096990A3 (en) Protein cages for the delivery of medical imaging and therapy
CY1110914T1 (el) Δικυκλο-πυραζολες δραστικες ως αναστολεις kinασων, διεργασια για την παρασκευη τους και φαρμακευτικες συνθεσεις που τις περιλαμβανουν
WO2003022852A3 (en) Furo-and thienopyrimidine derivatives as angiogenesis inhibitors
LU91928I2 (fr) Ipilimumab et ses dérivés pharmaceutiquement acceptables (YERVOY®)
ATE403657T1 (de) Chemische verbindungen
AU2002223684A1 (en) Combination comprising an agent decreasing vegf activity and an agent decreasing egf activity
JO2282B1 (en) Oxazole derivatives
WO2002080846A3 (en) Epothilone derivatives and methods for making and using the same
NO20044475L (no) 2-(2,6-diklorfenyl)-diarulimidazoler
AU2001235006A1 (en) Prophylactic and therapeutic monoclonal antibodies
DE60033649D1 (de) Verbindungen und therapeutische methoden
EP1264603B8 (en) Use of L-polynucleotides for in vivo imaging
CY1109087T1 (el) Ενωση ιμιδαζο[4,5-c]πυριδινης και μεθοδος αντι-ιικης θεραπειας
SE0003476D0 (sv) Compounds
DE60128100D1 (de) Analgetisches arzneimittel
TW200509970A (en) External skin treatment composition
MXPA03010737A (es) Aril-8-azabiciclo(3.2.1) octanos para tratamiento de depresion.
IT1320192B1 (it) Composizione terapeutica per la cura della psoriasi.
WO2002076400A3 (en) Inosine compounds and their use for treating or preventing an inflamation or a reperfusion disease
EP1436279B8 (en) Chemical compounds
CA2458932A1 (en) Methylene-4-azasteroids
IL150979A0 (en) 9-alkylamino-1-nitroacridine derivatives